Paul G. Richardson, Kenneth C. Anderson
Remedica, 2004 - Medical - 198 pages
Multiple myeloma, typically characterized by the accumulation of clonal plasma cells in multiple sites of the bone marrow, is the second most common hematologic malignancy with an incidence of 15,000 patients per year in the United States and a prevalence of approximately 50,000. Although the majority of patients respond to initial treatment with chemotherapy and radiation, most eventually relapse due to the proliferation of resistant tumor cells. Despite the advent of high dose chemotherapy with stem cell transplantation, multiple myeloma remains incurable, with approximately 12,000 deaths per annum recorded in the US from the disease. Over the last 10 years there has been a dramatic increase in our understanding of the biology of multiple myeloma which has provided insights into mechanisms of cytotoxic resistance both as inherent characteristics of the myeloma cell and the protective interaction between the tumor and its bone marrow microenvironment. Moreover, advances in our understanding of multiple myeloma pathogenesis have helped further define the intricacies of this complex disease. Through this greater understanding, a large array of new therapies have been engendered and a significant impact is being made on patient outcome as a result. This book provides a concise overview of the state of the art in multiple myeloma and should be of primary interest to clinicians as well as scientists and related caregivers alike in this rapidly changing field.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Multiple Myeloma: Translational and Emerging Therapies
Kenneth C. Anderson,M. Ghobrial Irene
Limited preview - 2007
acquired MDR activity adhesion agents allogeneic transplantation angiogenesis antiapoptotic apoptosis apoptotic ASCT autologous Barlogie bisphosphonates Blood BM microenvironment BMSCs bone disease bone resorption bortezomib Cancer Res Chauhan chemotherapy chromosome Clin Oncol clinical trials clodronate cyclophosphamide cytokines cytotoxic demonstrated dexamethasone dose doxorubicin drug resistance effects endothelial growth factor expression gene Haematol hematopoietic Hideshima high-dose chemotherapy human multiple myeloma human myeloma cells hypercalcemia increased induce inhibition integrin interleukin-6 intracellular lesions leukemia ligand malignant mechanisms mediated melphalan MGUS Mitsiades monoclonal gammopathy months multidrug resistance multiple myeloma multiple myeloma cells myeloma cell lines newly diagnosed novel novo MDR Oncogene osteoclast overall survival pamidronate paraprotein pathway PBSC Phase plasma cell plasmacytoma prednisone prognostic Rajkumar randomized trial receptor regimen relapsed remission renal failure response rate role serum signaling soluble stem cell transplantation stromal cells studies tandem transplants target thalidomide therapeutic therapy toxicity translocations treatment tumor cells vascular endothelial growth VEGF vitro zoledronate